Troy Groetken article, “Three Cases that Changed the Patent Disclosure Landscape of Proteins,” Featured in Drug Discovery & Development
Groetken explores the impacts of three opinions that have redefined what is considered adequate disclosure to support broad antibody claims in the first paragraph of 35 U.S. Code 112. Life sciences innovators must closely consider the three when planning and developing their patent portfolios. In particular, consideration should be given regarding the inclusion of sufficient support for protein-based claims to fully illustrate the inventor(s) were in possession of the full scope of the claims desired. Read the article here.